Showing results (1881-1890 of 4,565) with videos related to

Sort By:
Pageof 457
Advances in Therapy|December 14, 2020
Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical SettingLudovico Luca Sicignano, Donato Rigante, Beatrice Moccaldi, et al.
Advances in Therapy|November 12, 2022
Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn's Disease: Results from a Global Survey of Patients and GastroenterologistsMiguel Regueiro, Theresa Hunter, Rina Lukanova, et al.
Advances in Therapy|February 17, 2009
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapyMaureen J Lage, Rosalind Fabunmi, Kristina S Boye, et al.
Advances in Therapy|June 12, 2026
Advances in Clinical Cardiology 2025: A Summary of Key Clinical TrialsMatthew Todd, Patrick Savage, Michael Campbell, et al.
Advances in Therapy|March 31, 2026
Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature ReviewIsabelle Whittle, Eva Brown Hajdukova, Hannah Coles, et al.
Advances in Therapy|April 15, 2026
Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain StimulationTove Henriksen, Juan Carlos Martínez-Castrillo, Mark H B Huisman, et al.
Advances in Therapy|March 30, 2026
Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing SurveillanceAkemi Sebata, Takako Nagao, Tomoko Matsukawa, et al.
Advances in Therapy|April 30, 2026
Association Between Socioeconomic Indicators and Growth Hormone Treatment Patterns for Idiopathic Short Stature in China: A Large-Scale Real-World StudyChunxiu Gong, Xiaoping Luo, Ruimin Chen, et al.
Advances in Therapy|April 30, 2026
Low-Dose Naltrexone: What is the Evidence? A Narrative ReviewAmina H K Gouda, Nicholas E C Aitcheson, Kathryn J Steadman
Advances in Therapy|April 30, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse OutcomesDaniel Bandari, Devon Conway, Liang Dong, et al.
Pageof 457